We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Noncancerous Cells of the Tumor Microenvironment Skew Drug Effectiveness Assays

By LabMedica International staff writers
Posted on 24 Mar 2010
Print article
Cancer researchers have developed a system for screening drug candidate compounds that is based on cancer cells that are "co-cultured” with noncancerous cells in a format that mimics the natural tumor microenvironment.

Conventional anticancer drug screening is typically performed in the absence of noncancerous cells of the tumor microenvironment, which can profoundly alter antitumor drug activity. To address this limitation, investigators at the Dana-Farber Cancer Institute (Cambridge, MA, USA) developed a tumor cell-specific in vitro bioluminescence imaging (CS-BLI) assay. In this assay system tumor cells (for example, myeloma, leukemia, and solid tumors) that stably express the gene for the enzyme luciferase are cultured with nonmalignant accessory cells (for example, stromal cells) for the selective quantification of tumor cell viability following drug treatment. The test is carried out in parallel on cultures of the tumor cells lacking the presence of stromal cells. CS-BLI is a high-throughput assay system that is able to identify stroma-induced chemo-resistance in various types of cancer.

The assay measures the amount of light emitted by living cancer cells. After treatment with a drug candidate, reduction in the amount of light being emitted indicates how proficient the drug was at killing tumor cells, and whether this effectiveness changes when normal cells are around the tumor. To determine whether the candidate compound is also toxic to normal cells, a "counter-screen,” is conducted to measure the effect of the compound on normal cells.

Results published in the March 14, 2010, online edition of the journal Nature Medicine revealed that in general drug candidates that acted powerfully against isolated samples of tumor cells were significantly less effective against the same types of tumor cells co-cultured with nonmalignant cells. However, in an exception to this trend, they found that the drug candidate reversine was more active against myeloma tumor cells when the cells were in contact with healthy cells of the bone marrow.

"Despite their often impressive results in the laboratory, for every 100 potential anticancer therapies administered in patients in clinical trials, only about eight prove safe and effective enough to receive Food and Drug Administration approval,” said senior author Dr. Constantine Mitsiades, professor of medical oncology at the Dana-Farber Cancer Institute. "This success rate is clearly not as high as we would like it to be, and one reason may be that so far we have not had a good way to account, at the earliest stages of laboratory testing, for the impact of the tumor microenvironment on these drugs.”

"The technique also provides a powerful tool for determining which biological mechanisms allow cancers to become resistant to certain treatments and which new therapies can neutralize those mechanisms,” said Dr. Mitsiades. "It will be of use in prioritizing candidate drugs for further rigorous study of their properties before embarking on clinical trials. This technique may show that the classical methods of studying candidate cancer drugs in laboratory conditions have overestimated the effectiveness of some agents, and underestimated others.

Related Links:
Dana-Farber Cancer Institute

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Binocular Laboratory LED Illuminated Microscope
HumaScope Classic LED
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Molecular Diagnostics

view channel
Image: Researcher Kanta Horie places a sample in a mass spectrometer that measures protein levels in blood plasma and other fluids (Photo courtesy of WashU Medicine)

Highly Accurate Blood Test Diagnoses Alzheimer’s and Measures Dementia Progression

Several blood tests are currently available to assist doctors in diagnosing Alzheimer's disease in individuals experiencing cognitive symptoms. However, these tests do not provide insights into the clinical... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.